Ibrutinib Treatment for First-Line and Relapsed/Refractory CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Clin. Cancer Res 2020 Mar 24;[EPub Ahead of Print], JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, K Blum, JP Sharman, W Wierda, W Zhao, NA Heerema, Y Luan, EA Liu, JP Dean, S O'BrienFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.